ArticleInfectious agents and cancer2026
High-risk human papillomavirus genotypes in cervical squamous cell carcinomas diagnosed in Rwanda.
Article in Infectious agents and cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
backgroundCervical cancer is driven by long persisting high-risk HPV infections(hrHPV). HIV+ women with hrHPV co-infections are sixfold more likely to develop cervical cancer compared with HIV- women. To inform Rwandan policy on HPV vaccines and screening strategies, we assessed the distribution of hrHPV types in cervical cancer tissue overall and by HIV status.
methodsWe retrieved all cervical squamous cell carcinomas (SCCs) diagnosed between 2018 and 2021 from three referral health facilities in Kigali, Rwanda (n = 415); tissues for 107 cases could not be retrieved. Of the remaining 308 cases, the H&E-stained slides from formalin-fixed, paraffin-embedded tissue for every case underwent a histological review, medical records were extracted, and tissue blocks were selected for HPV genotyping. AmpFire HPV genotyping test (Atila BioSystems, Sunnyvale, CA, USA) was used to test for HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, and 68. We compared HPV type distribution by HIV status. STATA 17 (StataCorp LLC, College Station, Texas, USA) was used for data analysis.
resultsTwo hundred-five cases (60%) had valid HPV genotyping results; 71 (34.6%) were HIV-, 32 (15.6%) were HIV+, and 102 (49.8%) had an unknown HIV status. The mean age was 57.7 (± 11.8) years, ~ 60% were married, and 54% were FIGO stage 3 or 4. Most cervical SCCs (90.2%, n = 185) tested positive for hrHPV. There was no significant difference for overall and type-specific hrHPV positivity between positive, negative, and unknown HIV status except for HPV31 (p = 0.002), HPV35 (p < 0.001), and HPV68 (p = 0.005); HPV31-positive SCCs were more common in women living with HIV than in HIV-negative women (p = 0.008).
conclusionsThere were few differences in the HPV type distribution between known HIV + and HIV- women. Importantly, currently available HPV vaccines in Rwanda do not target HPV31 and no commercially available HPV vaccine targets HPV35. This highlights the need to advocate for access to vaccines targeting those HPV types for optimized cervical cancer prevention.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.